Treatment increases the chances of a successful kidney transplant
A new treatment that increases the chance of a successful kidney transplant has been recommended by NICE in final draft guidance. (Source: NHS Networks)
Source: NHS Networks - June 21, 2022 Category: UK Health Source Type: news

Breakthrough kidney transplant operation can prevent the need for immunosuppressant drugs
Stanford doctors performed a breakthrough kidney transplant on a pair of Alabama siblings that makes it so they do not need to use immunosuppressants. (Source: the Mail online | Health)
Source: the Mail online | Health - June 16, 2022 Category: Consumer Health News Source Type: news

Technique Eliminates Need for Prolonged Immunosuppression in Kidney Transplants Technique Eliminates Need for Prolonged Immunosuppression in Kidney Transplants
Doctors at Stanford University School of Medicine in California say they have developed a way to transplant kidneys without the need for long-term immunosuppression.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2022 Category: Consumer Health News Tags: Transplantation News Source Type: news

Doctors Transplant Kidneys to Children Without Need for Immune-Suppressing Drugs
Title: Doctors Transplant Kidneys to Children Without Need for Immune-Suppressing DrugsCategory: Health NewsCreated: 6/16/2022 12:00:00 AMLast Editorial Review: 6/16/2022 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - June 16, 2022 Category: Nutrition Source Type: news

Transplant Success Without Immune Suppressive Drugs
(MedPage Today) -- For three children, their newly transplanted kidneys might never require them to take immunosuppressive drugs. Along with the kidney they got from a parent due to the rare T-cell immunodeficiency and primary kidney failure syndrome... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - June 15, 2022 Category: Surgery Source Type: news

Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Increased Ischemic Heart Disease Risk After Kidney Donation Increased Ischemic Heart Disease Risk After Kidney Donation
Are kidney donors at a greater risk for developing ischemic heart disease? A new study looks at the possible long-term risks.Nephrology Dialysis Transplantation (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - June 8, 2022 Category: Transplant Surgery Tags: Nephrology Journal Article Source Type: news

AHA News: Grammy Winner, Chart-Topping Producer – and Kidney Transplant Recipient
Title: AHA News: Grammy Winner, Chart-Topping Producer – and Kidney Transplant RecipientCategory: Health NewsCreated: 6/6/2022 12:00:00 AMLast Editorial Review: 6/7/2022 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 7, 2022 Category: Cardiology Source Type: news

AHA News: Grammy Winner, Chart-Topping Producer – and Kidney Transplant Recipient
MONDAY, June 6, 2022 (American Heart Association News) -- Brian Kennedy was living his dream. A piano prodigy, he moved from his hometown of Kansas City, Missouri, to Los Angeles in 2003, when he was 20. He started out as a musician for hire,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 6, 2022 Category: General Medicine Source Type: news

Updated Data for Janssen ’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is being studied in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 The data were featured as part of an oral session during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Additional poster presentations f...
Source: Johnson and Johnson - June 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news

Covid: Peterborough kidney patient still shielding
A 70-year-old kidney transplant patient is waiting for a drug to be reapproved. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - May 30, 2022 Category: Consumer Health News Source Type: news

When Should Those With End-Stage Kidney Disease Forego Dialysis? When Should Those With End-Stage Kidney Disease Forego Dialysis?
Australia and the UK have long had programs whereby some elderly patients with end-stage kidney disease, or those with many comorbidities, opt to forego dialysis, but the US has lagged behind.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 23, 2022 Category: Transplant Surgery Tags: Nephrology News Source Type: news